**PKR JAIN HEALTHCARE INSTITUTE** NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. BHAGWANT KAUR				
AGE/ GENDER : 55 YRS/FEMALE			PATIENT ID	: 1661850	
COLLECTED BY	:		REG. NO./LAB NO.	: 122411050024	
REFERRED BY:BARCODE NO.: 12505464CLIENT CODE.: P.K.R JAIN HEALTHCARE INSTITUTE			<b>REGISTRATION DATE</b>	: 05/Nov/2024 02:13 PM	
			COLLECTION DATE	:05/Nov/202402:43PM	
		STITUTE	<b>REPORTING DATE</b>	: 05/Nov/2024 03:39PM	
CLIENT ADDRESS					
Test Name		Value	Unit	<b>Biological Reference interval</b>	
	CLINIC	CAL CHEMIS	STRY/BIOCHEMIST	RY	
		LIPID PR	OFILE : BASIC		
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP		181.01	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		234.4 <sup>H</sup>	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTERO: by SELECTIVE INHIBIT	L (DIRECT): SERUM 10N	63.53	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROI by CALCULATED, SPE		70.6	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLEST by CALCULATED, SPE	LING BI BEITOIN	117.48	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTER		46.88 <sup>H</sup>	mg/dL	0.00 - 45.00	
by CALCULATED, SPE TOTAL LIPIDS: SER by CALCULATED, SPE		596.42	mg/dL	350.00 - 700.00	
CHOLESTEROL/HD	DL RATIO: SERUM	2.85	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0	

**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

**NOT VALID FOR MEDICO LEGAL PURPOSE** 

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 



## PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana) A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. BHAGWANT KAUR				
AGE/ GENDER	: 55 YRS/FEMALE	PATIENT ID	: 1661850		
<b>COLLECTED BY</b>	:	<b>REG. NO./LAB NO.</b>	: 122411050024		
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 05/Nov/2024 02:13 PM		
BARCODE NO.	: 12505464	<b>COLLECTION DATE</b>	:05/Nov/202402:43PM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	<b>REPORTING DATE</b>	:05/Nov/202403:39PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA				
Test Name	Value	Unit	<b>Biological Reference interval</b>		

			MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM by Calculated, Spectrophotometry	1.11	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM	3.69	RATIO	3.00 - 5.00

## **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDI

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 

